

BOSTON SCIENTIFIC ANNOUNCES 1000TH EUROPEAN PATIENT USING LATITUDE[®] PATIENT MANAGEMENT SYSTEM

Value of the service recognized by patients and physicians

Paris, France (March 15th, 2010) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has reached the milestone of 1000 European patients using its LATITUDE[®] Patient Management System. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient's heart health status. The system can also transmit relevant event notifications between scheduled hospital visits directly to a patient's physician.

One of the patients using the system, Gritt Liebing, age 44 years of Darmstadt, Germany explained, "The LATITUDE system is brilliant. On a practical level I do not need to call or visit the hospital as much, which means I have more time for my normal life and my sports activities. Also my family and I have the added reassurance and peace of mind that the system will alert my doctor if any problems are detected. I would not want to go back to the way it was before I used the system."

"I am really impressed with the LATITUDE system and service," said Dr. Haran Burri of Hôpitaux Universitaires of Geneva, Switzerland. "With LATITUDE, I can choose to customize and receive information that enables me to optimize patient treatment. I also value and appreciate the support I receive from Boston Scientific, from helping train my staff to answering questions through their dedicated support center."

LATITUDE is the only cardiac patient monitoring system that can be associated with a wireless weight scale and blood pressure monitor, thus enabling compliance with European Society of Cardiology Class 1 recommendations on management of heart failure patients.

"This progress demonstrates that the benefits of our LATITUDE system are recognised and valued by both physicians and patients," said Fred Hrkac, President of Europe, Middle East and Africa (EMEA) for Boston Scientific. "This is another exciting milestone for our Company, spanning from the first human implant of the ICD 30 years ago to manufacturing the smallest, thinnest high-energy devices today. We expect continued success for the LATITUDE system as the advantages of remote monitoring technology provide a significant opportunity to further improve patient care."

The international version of the LATITUDE system is compatible with the Company's wireless TELIGEN[®] implantable cardioverter defibrillator (ICD) and COGNIS[®] cardiac resynchronization therapy defibrillator (CRT-D), the world's smallest and thinnest high-energy devices.

A video testimony of Gritt Liebing can be viewed at

http://www.bostonscientific.com/templatedata/imports/multimedia/CRM/LATITUDE_Liebing_Intl.wmv

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Geraldine Varoqui, Director International Public Relation, Tel: +49 2102 489 461, Mob: +49 170 782 85 58, varoquig@bsci.com